| Literature DB >> 33534017 |
Azin Shayganfar1, Ramin Sami2, Somayeh Sadeghi2, Mehrnegar Dehghan3, Nilufar Khademi3, Reyhaneh Rikhtehgaran4, Reza Basiratnia1, Felora Ferdosi1, Somayeh Hajiahmadi5.
Abstract
BACKGROUND: The COVID-19 pandemic is straining the health care systems worldwide. Therefore, health systems should make strategic shifts to ensure that limited resources provide the highest benefit for COVID-19 patients.Entities:
Keywords: COVID-19; Coronavirus; Poor outcome; Risk factor
Mesh:
Year: 2021 PMID: 33534017 PMCID: PMC7856446 DOI: 10.1007/s10140-021-01903-8
Source DB: PubMed Journal: Emerg Radiol ISSN: 1070-3004
Fig. 1An 81-year-old man with positive RT-PCR; symptoms: severe; CT findings: ground-glass opacities in both central and peripheral zones of both lungs without craniocaudal predilection; CT score: 14; outcome: mechanical ventilation
Baseline characteristics of the study population according to discharge or ICU/death status
| Variables | Total ( | Discharge ( | ICU/death ( | ||
|---|---|---|---|---|---|
| Age(years) | 57.5 ± 16.1 | 54.9 ± 15.9 | 67 ± 13.2 | < 0.001 | |
| Age group (%) | 20–30 | 8 (4.5) | 8 (5.8) | 0 | 0.001 |
| 30–40 | 18 (10.2) | 17 (12.3) | 1 (2.6) | ||
| 40–50 | 26 (14.8) | 24 (17.4) | 2 (5.3) | ||
| 50–60 | 45 (25.6) | 37 (26.8) | 8 (21.1) | ||
| 60–70 | 38 (21.6) | 25 (18.1) | 13 (34.2) | ||
| 70–80 | 24 (13.6) | 19 (13.8) | 5 (13.2) | ||
| 80–90 | 17 (9.7) | 8 (5.8) | 9 (23.7) | ||
| Gender | Males (%) | 108 (61.4) | 81 (58.7) | 27 (71.1) | 0.166 |
| Females (%) | 68 (38.6) | 57 (41.3) | 11 (28.9) | ||
| Previous medical history | |||||
| HTN | 54 (30.7) | 43 (31.2) | 11 (28.9) | 0.793 | |
| Cardiovascular disease (%) | 34 (19.3) | 20 (14.5) | 14 (36.8) | 0.002 | |
| DM (%) | 39 (22.2) | 31 (22.5) | 8 (21.1) | 0.853 | |
| Chronic respiratory disease (%) | 16 (9.1) | 12 (8.7) | 4 (10.4) | 0.728 | |
| Cancer (%) | 3 (1.7) | 2 (1.4) | 1 (2.6) | 0.618 | |
| CKD (%) | 15 (8.5) | 10 (7.2) | 5 (13.2) | 0.248 | |
| HLP (%) | 12 (6.8) | 11 (8) | 1 (2.6) | 0.248 | |
| Clinical and laboratory data | |||||
| Lymphocyte (%) | 1119.15 ± 1418.8 | 1179.05 ± 1579.3 | 893.26 ± 389.2 | 0.291 | |
| O2 saturation (%) | 89.19 ± 6.9 | 90.29 ± 5.9 | 85.21 ± 8.6 | < 0.001 | |
| Respiratory rates (rates/minute) | 21.42 ± 5.1 | 21.13 ± 5.1 | 22.44 ± 5 | 0.162 | |
| CT findings | |||||
| CT score | 10.58 ± 5.6 | 9.53 ± 5.1 | 14.39 ± 5.8 | < 0.001 | |
| Ground-glass opacity (%) | 70 (39.8) | 51 (37) | 19 (50) | 0.146 | |
| Mixed ground-glass opacity and consolidation (%) | 82 (46.6) | 64 (46.4) | 18 (47.4) | 0.914 | |
| Consolidation (%) | 17 (9.7) | 17 (12.3) | 0 | 0.023 | |
| Centrilobular nodules (%) | 8 (4.5) | 7 (5.1) | 1 (2.6) | 0.522 | |
| Bronchial wall thickening (%) | 14 (8) | 10 (7.2) | 4 (10.5) | 0.508 | |
| Reticulation (%) | 73 (41.5) | 57 (41.3) | 16 (42.1) | 0.929 | |
| Vascular enlargement (%) | 13 (7.4) | 11 (8) | 2 (5.3) | 0.572 | |
| Pleural effusion (%) | 9 (5.1) | 8 (5.8) | 1 (2.6) | 0.433 | |
| Upper or lower involvement (%) | Upper | 5 (2.8) | 5 (3.6) | 0 | 0.101 |
| Lower | 89 (50.6) | 74 (53.6) | 15 (39.5) | ||
| None | 82 (46.6) | 59 (42.8) | 23 (60.5) | ||
| Unilateral/bilateral (%) | Unilateral | 22 (12.5) | 21 (15.2) | 1 (2.6) | 0.038 |
| Bilateral | 154 (87.5) | 117 (84.8) | 37 (97.4) | ||
| Central/peripheral/none (%) | Central | 9 (5.1) | 7 (5.1) | 2 (5.3) | 0.880 |
| Peripheral | 108 (61.4) | 86 (62.3) | 22 (57.9) | ||
| None | 59 (33.5) | 45 (32.6) | 14 (36.8) | ||
| Focal/multifocal/diffuse (%) | Focal | 17 (9.7) | 16 (11.6) | 1 (2.6) | 0.107 |
| Multifocal | 155 (88.1) | 120 (87) | 35 (92.1) | ||
| Diffuse | 4 (2.3) | 2 (1.4) | 2 (5.3) | ||
Fig. 2ROC curve based on age among the study population
Fig. 3ROC curve based on CT score among the study population
Fig. 4ROC curve based on O2 saturation among the study population
The multivariable-adjusted odds ratio of death/ICU status according to age, CT score, and O2 saturation
| Models | Age | CT score | O2 saturation | ||||||
|---|---|---|---|---|---|---|---|---|---|
| < 60 | ≥ 60 | < 10.5 | ≥ 10.5 | > 90.5 | ≤ 90.5 | ||||
| Crude | 1.00 | 4.05 (1.85–8.86) | < 0.001 | 1.00 | 3.86 (1.74–8.57) | 0.001 | 1.00 | 4.10 (1.84–9.10) | 0.001 |
| Model 1* | 1.00 | 3.95 (1.80–8.66) | 0.001 | 1.00 | 3.69 (1.61–8.46) | 0.002 | 1.00 | 2.99 (1.28–6.95) | 0.011 |
| Model 2** | 1.00 | 3.62 (1.35–9.67) | 0.019 | 1.00 | 4.38 (1.69–11.35) | 0.002 | 1.00 | 2.78 (1.03–7.47) | 0.042 |
*Adjusted for age and sex
**Adjusted for age, sex, CT score, lymphocytes, O2 saturation, HTN, DM, COPD, cancer, CKD, HLP with the exception of the desired variable